Form D · Biotechnology

CardioVascular BioTherapeutics, Inc.

Las Vegas, NV · CIK 0001303497

Offering snapshot reported Jan 14, 2015 · SEC filing

Reported sold
Yet to sell
Offering amount: $49M
Investors reported
0
Form D · investor count
Minimum accepted
$1K
Reported outside-investor minimum
First sale
Yet to occur
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jan 14, 2015InitialYet to sellNo comparison0SEC filing
Apr 14, 2008PaperNot reportedNo comparisonNot reported
Apr 14, 2008PaperNot reportedNo comparisonNot reportedSEC filing
Mar 27, 2006PaperNot reportedNo comparisonNot reported

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0 (estimated)
Finders' fees
$0 (estimated)
Form D file number
021-232247

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
NoneNone

Source: Form D, filed Jan 14, 2015. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Robert Wayne Blackburn Director
Mickael A Flaa Executive
Grant Gordon Director
Al Moran Director
James R Richards Director
Jon Ross Director
Robert Schleizer Director
Calvin A Wallen Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
9500 Hillwood Drive, Suite 200 A
Las Vegas, NV, 89134